Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $223.00.

KRYS has been the subject of several research analyst reports. Chardan Capital dropped their target price on shares of Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research report on Friday, August 22nd. Bank of America upped their target price on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a research report on Friday, October 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Krystal Biotech in a research note on Wednesday, October 8th. Citigroup reaffirmed a “neutral” rating and set a $166.00 price target (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday, August 5th. Finally, Guggenheim set a $224.00 price objective on Krystal Biotech and gave the stock a “buy” rating in a report on Friday, October 17th.

Krystal Biotech Stock Up 2.0%

Krystal Biotech stock opened at $189.93 on Tuesday. The stock has a market cap of $5.50 billion, a price-to-earnings ratio of 38.60 and a beta of 0.64. The business has a 50-day simple moving average of $165.86 and a 200 day simple moving average of $152.11. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $207.84.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. On average, research analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Crossmark Global Holdings Inc. increased its position in Krystal Biotech by 2.7% during the 1st quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company’s stock valued at $427,000 after buying an additional 63 shares in the last quarter. Main Management ETF Advisors LLC increased its position in Krystal Biotech by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 5,131 shares of the company’s stock valued at $705,000 after buying an additional 84 shares in the last quarter. M&T Bank Corp increased its position in Krystal Biotech by 2.3% during the 2nd quarter. M&T Bank Corp now owns 3,785 shares of the company’s stock valued at $520,000 after buying an additional 85 shares in the last quarter. Xponance Inc. increased its position in Krystal Biotech by 4.9% during the 1st quarter. Xponance Inc. now owns 1,873 shares of the company’s stock valued at $338,000 after buying an additional 88 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC increased its holdings in shares of Krystal Biotech by 6.7% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company’s stock worth $273,000 after purchasing an additional 95 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).